Johnson & Johnson
Public companyUS1 field
Where it works
| Technology | ||
|---|---|---|
| NanotechnologyLicenses and runs global development of Nanobiotix's NBTXR3 nanoparticle as JNJ-1900. | Licenses and runs global development of Nanobiotix's NBTXR3 nanoparticle as JNJ-1900. | sec.gov |
Events
| Date | Event | ||
|---|---|---|---|
| Mar 30, 2026 | First randomized Phase 2 data for JNJ-1900 in stage 3 lung cancersec.gov· Milestone· Nanotechnology | Nanotechnology | Milestone |
| Jul 7, 2025 | European regulators reclassify NBTXR3 from device to medicinal productsec.gov· Policy· Nanotechnology | Nanotechnology | Policy |
| Mar 17, 2025 | Nanobiotix amends its NBTXR3 licensing deal with Johnson & Johnsonsec.gov· Deal· Nanotechnology | Nanotechnology | Deal |
About
- Source
- sec.gov (filing, added by seed)
- First seen
- Sep 25, 2026
- Last seen
- Sep 25, 2026
| Date | Change | ||
|---|---|---|---|
| Sep 25, 2026 | Johnson & JohnsonCompany in Nanotechnology: Joined a field, Licenses and runs global development of Nanobiotix's NBTXR3 nanoparticle as JNJ-1900. | seed | sec.gov |
| Sep 25, 2026 | Johnson & JohnsonCompany: Added | seed | sec.gov |